New Drug Therapies Are Easing the Burden of Anti-VEGF Treatments
Treatments for neovascularization in the retina may be reduced to as few as two to four times per year. New anti-VEGF drug therapies are now available for treatment of macular diseases. Over the past two years the U.S. Food and Drug Administration (FDA) has approved less invasive, less burdensome, and lower cost drugs and procedures. […]